APLS
Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
$41.02
+0.00% today
Updated 2026-05-14
Market cap
$5.25B
P/E ratio
38.34
P/S ratio
4.75x
EPS (TTM)
$1.07
Dividend yield
—
52W range
$16 – $41
Volume
7.4M
Apellis Pharmaceuticals Inc (APLS) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$41.02
12-Month target
$1.22
2030 Target
—
Intrinsic (DCF)
$194.37
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.4B | $0.8B | $1.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 12.10%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.